Acquired hyperpigmentations

Tania Ferreira Cestari, Lia Pinheiro Dantas, Juliana Catucci Boza, Tania Ferreira Cestari, Lia Pinheiro Dantas, Juliana Catucci Boza

Abstract

Cutaneous hyperpigmentations are frequent complaints, motivating around 8.5% of all dermatological consultations in our country. They can be congenital, with different patterns of inheritance, or acquired in consequence of skin problems, systemic diseases or secondary to environmental factors. The vast majority of them are linked to alterations on the pigment melanin, induced by different mechanisms. This review will focus on the major acquired hyperpigmentations associated with increased melanin, reviewing their mechanisms of action and possible preventive measures. Particularly prominent aspects of diagnosis and therapy will be emphasized, with focus on melasma, post-inflammatory hyperpigmentation, periorbital pigmentation, dermatosis papulosa nigra, phytophotodermatoses, flagellate dermatosis, erythema dyschromicum perstans, cervical poikiloderma (Poikiloderma of Civatte), acanthosis nigricans, cutaneous amyloidosis and reticulated confluent dermatitis.

Conflict of interest statement

Conflict of Interest: None.

Figures

FIGURE 1
FIGURE 1
Acquired hyperpigmentations. Moderate melasma, brown spots with irregular edges affecting the right hemiface, following a mandibular pattern in a patient with phototype V
FIGURE 2
FIGURE 2
Acquired hyperpigmentations. Severe melasma. Patient with skin phototype IV, presenting a somewhat homogeneous lesions, but with intense pigmentation, predominantly in the middle facial region
FIGURE 3
FIGURE 3
Acquired hyperpigmentations. Postinflammatory hyperpigmentation – bluish brown macules distributed around the trunk, secondary to extensive pityriasis rosea
FIGURE 4
FIGURE 4
Acquired hyperpigmentations. Periorbital hyperpigmentations – Depression and shaded aspect, with visualization of the superficial vascular network in the infraorbital region of a 38 years-old woman
FIGURE 5
FIGURE 5
Acquired hyperpigmentations. Phytophotodermatoses – hyperchromic brown spots, with a leaked aspect, located on the dorsal area of the hand and fingers, secondary to accidental contact with lemon juice followed by sun exposure
FIGURE 6
FIGURE 6
Acquired hyperpigmentations. Flagellate Dermatitis– Linear urticariform lesions, some with a slight superficial blistering, located on the lateral side of the chest, which appeared 15 days after the initiation of treatment with bleomycin
FIGURE 7
FIGURE 7
Acquired hyperpigmentations. Erythema Dyschromicum Perstans – Grayish macules of varying sizes, located on the anterior region of the thorax, abdomen and upper thighs of a 27 years-old woman
FIGURE 8
FIGURE 8
Acquired hyperpigmentations. Poikiloderma of Civatte. Note the grid-like hyperpigmentation, affecting the lateral areas and base of the neck in a 51 years-old phototype 3 woman. Observe photodamage lesions and a lighter area correspondings to the region shaded by the chin
FIGURE 9
FIGURE 9
Acquired hyperpigmentations. Acanthosis nigricans – Linear and coalescent papular hyperpigmentation, with velvety aspect, located in the axillary region of an obese adolescent
FIGURE 10
FIGURE 10
Acquired hyperpigmentations. Macular amyloidosis– a brownish itchy area, located in the dorsal region, corresponding to the range area of a dextral patient’s hand
FIGURE 11
FIGURE 11
Acquired hyperpigmentations. Amyloid lichen – plaque formed by the confluence of small grayishbrown papules located in the pretibial region

References

    1. Censo Dermatologico da SBD. Brazilian Society of Dermatology Web page - Dermatological census. [Acesso 1 Dez. 2012]. [Internet] Disponível em: .
    1. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC., Jr Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698–710.
    1. Ritter CG, Fiss DV, Borges da Costa JA, de Carvalho RR, Bauermann G, Cestari TF. Extra-facial melasma: clinical, histopathological, and immunohistochemical case-control study. J Eur Acad Dermatol Venereol. 2013;27:1088–1094.
    1. Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin. 2003;21:601–607.
    1. Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013;27:151–156.
    1. Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men: a clinical, aetiological and histological study. J Eur Acad Dermatol Venereol. 2010;24:768–772.
    1. Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011;56:380–382.
    1. Cestari T, Benvenuto-Andrade C. Hyperpigmentation and melasma: a physiopathologic review for the clinical dermatologist. Cosm Dermatol. 2005;18:703–706.
    1. Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002;146:228–237.
    1. Miot LD, Miot HA, Silva MG, Marques ME. Physiopathology of melasma. An Bras Dermatol. 2009;84:623–635.
    1. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254–1262.
    1. Kang HY, Ortonne JP. What should be considered in the treatment of melasma? Ann Dermatol. 2010;22:373–378.
    1. Mahmoud BH, Ruvolo E, Hexsel CL, Liu Y, Owen MR, Kollias N, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2010;130:2092–2097.
    1. Hernández-Barrera R, Torres-Alvarez B, Castanedo-Cazares JP, Oros-Ovalle C, Moncada B. Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma. Clin Exp Dermatol. 2008;33:305–308.
    1. Shin J, Kim JH, Kim EK. Repeated exposure of human fibroblasts to UVR induces secretion of stem cell factor and senescence. J Eur Acad Dermatol Venereol. 2012;26:1577–1580.
    1. Jang YH, Lee JY, Kang HY, Lee ES, Kim YC. Oestrogen and progesterone receptor expression in melasma: an immunohistochemical analysis. J Eur Acad Dermatol Venereol. 2010;24:1312–1316.
    1. Pérez M, Sánchez JL, Aguiló F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol. 1983;81:543–545.
    1. Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol. 2007;6:195–202.
    1. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011;65:689–689.
    1. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27:96–101.
    1. Cestari T, Arellano I, Hexsel D, Ortonne JP, Latin American Pigmentary Disorders Academy Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23:760–772.
    1. Arellano I, Cestari T, Ocampo-Candiani J, Azulay-Abulafia L, Bezerra Trindade P, Neto, Hexsel D, et al. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity. J Eur Acad Dermatol Venereol. 2012;26:611–618.
    1. Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010:
    1. Kang HY, Valerio L, Bahadoran P, Ortonne JP. The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review. Am J Clin Dermatol. 2009;10:251–260.
    1. Kang HY, Valerio L, Bahadoran P, Ortonne JP. Treatment of melasma. Am J Clin Dermatol. 2009;10:251–260.
    1. Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011;65:699–714.
    1. Alikhan A, Daly M, Wu J, Balkrishnan R, Feldman SR. Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States. J Dermatolog Treat. 2010;21:276–281.
    1. Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol. 2011 Dec;10(4):282–287.
    1. Magalhães GM, Borges MFB, Queiroz ARC, Capp AA, Pedrosa SV, Diniz MS. Estudo duplo-cego e randomizado do peeling de ácido retinoico a 5% e 10% no tratamento do melasma: avaliação clínica e impacto na qualidade de vida. Doubleblind randomized study of 5% and 10% retinoic acid peels in the treatment of melasma: clinical evaluation and impact on the quality of life. Surg Cosmet Dermatol. 2011;1:317–322.
    1. Zaleski L, Fabi S, Goldman MP. Treatment of melasma and the use of intense pulsed light: a review. J Drugs Dermatol. 2012;11:1316–1320.
    1. Zoccali G, Piccolo D, Allegra P, Giuliani M. Melasma treated with intense pulsed light. Aesthetic Plast Surg. 2010;34:486–493.
    1. Na SY, Cho S, Lee JH. Intense pulsed light and low-fluence Q-switched Nd:YAG laser treatment in melasma patients. Ann Dermatol. 2012;24:267–273.
    1. Arora P, Sarkar R, Garg VK, Arya L. Lasers for treatment of melasma and postinflammatory hyperpigmentation. J Cutan Aesthet Surg. 2012;5:93–103.
    1. Chan HH, Kono T. The use of lasers and intense pulsed light sources for the treatment of pigmentary lesions. Skin Therapy Lett. 2004;9:5–7.
    1. Kauvar AN. Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers. Lasers Surg Med. 2012;44:117–124.
    1. Niwa Massaki AB, Eimpunth S, Fabi SG, Guiha I, Groff W, Fitzpatrick R. Treatment of melasma with the 1,927-nm fractional thulium fiber laser: A retrospective analysis of 20 cases with long-term follow-up. Lasers Surg Med. 2013;45:95–101.
    1. Cho HH, Choi M, Cho S, Lee JH. Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser. J Dermatolog Treat. 2013;24:292–296.
    1. Fitzpatrick RE, Lupton JR. Successful treatment of treatment-resistant laser-induced pigment darkening of a cosmetic tattoo. Lasers Surg Med. 2000;27:358–361.
    1. Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, doubleblind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. Int J Dermatol. 2009;48:896–901.
    1. Hwang SW, Oh DJ, Lee D, Kim JW, Park SW. Clinical efficacy of 25% L-ascorbic acid (C'ensil) in the treatment of melasma. J Cutan Med Surg. 2009;13:74–81.
    1. Sobhi RM, Sobhi AM. A single-blinded comparative study between the use of glycolic acid 70% peel and the use of topical nanosome vitamin C iontophoresis in the treatment of melasma. J Cosmet Dermatol. 2012;11:65–71.
    1. Wanick FBF, Zink BS, Lopes RF. Avaliação da eficácia do licopeno, betacaroteno e Lactobacillus johnsonii no tratamento de manutenção do melasma durante o verão: um estudo comparativo. Efficacy evaluation of lycopene, beta-carotene and Lactobacillus johnsonii in the maintenance treatment of melasma during the summer: a comparative study. Surg Cosmet Dermatol. 2011;3:297–301.
    1. Taylor S, Grimes P, Lim J, Im S, Lui H. Postinflammatory hyperpigmentation. J Cutan Med Surg. 2009;13:183–191.
    1. Chan HH, Manstein D, Yu CS, Shek S, Kono T, Wei WI. The prevalence and risk factors of post-inflammatory hyperpigmentation after fractional resurfacing in Asians. Lasers Surg Med. 2007;39:381–385.
    1. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009;28:77–85.
    1. Stratigos AJ, Katsambas AD. Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am J Clin Dermatol. 2004;5:161–168.
    1. Ortonne JP, Bissett DL. Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc. 2008;13:10–14.
    1. Javaheri SM, Handa S, Kaur I, Kumar B. Safety and efficacy of glycolic acid facial peel in Indian women with melasma. Int J Dermatol. 2001;40:354–357.
    1. Chan HH. Effective and safe use of lasers, light sources, and radiofrequency devices in the clinical management of Asian patients with selected dermatoses. Lasers Surg Med. 2005;37:179–185.
    1. Cho SB, Park SJ, Kim JS, Kim MJ, Bu TS. Treatment of post-inflammatory hyperpigmentation using 1064-nm Q-switched Nd:YAG laser with low fluence: report of three cases. J Eur Acad Dermatol Venereol. 2009;23:1206–1207.
    1. Katz TM, Goldberg LH, Firoz BF, Friedman PM. Fractional photothermolysis for the treatment of post inflammatory hyperpigmentation. Dermatol Surg. 2009;35:1844–1848.
    1. Freitag FM, Cestari TF. What causes dark circles under the eyes? J Cosmet Dermatol. 2007;6:211–215.
    1. Roh MR, Chung KY. Infraorbital dark circles: definition, causes, and treatment options. Dermatol Surg. 2009;35:1163–1171.
    1. Mitsuishi T, Shimoda T, Mitsui Y, Kuriyama Y, Kawana S. The effects of topical application of phytonadione, retinol and vitamins C and E on infraorbital dark circles and wrinkles of the lower eyelids. J Cosmet Dermatol. 2004;3:73–75.
    1. Momosawa A, Kurita M, Ozaki M, Miyamoto S, Kobayashi Y, Ban I, et al. Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians. Plast Reconstr Surg. 2008;121:282–288.
    1. Ohshima H, Mizukoshi K, Oyobikawa M, Matsumoto K, Takiwaki H, Kanto H, et al. Effects of vitamin C on dark circles of the lower eyelids: quantitative evaluation using image analysis and echogram. Skin Res Technol. 2009;15:214–217.
    1. Roh MR, Kim TK, Chung KY. Treatment of infraorbital dark circles by autologous fat transplantation: a pilot study. Br J Dermatol. 2009;160:1022–1025.
    1. Palumbo A, d'Ischia M, Misuraca G, Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta. 1991;1073:85–90.
    1. Ma G, Lin XX, Hu XJ, Jin YB, Chen H. Treatment of venous infraorbital dark circles using a long-pulsed 1,064-nm neodymium-doped yttrium aluminum garnet laser. Dermatol Surg. 2012;38:1277–1282.
    1. Xu TH, Yang ZH, Li YH, Chen JZ, Guo S, Wu Y, et al. Treatment of infraorbital dark circles using a low-fluence Q-switched 1,064-nm laser. Dermatol Surg. 2011;37:797–803.
    1. Niang SO, Kane A, Diallo M, Choutah F, Dieng MT, Ndiaye B. Dermatosis papulosa nigra in Dakar, Senegal. Int J Dermatol. 2007;46:45–47.
    1. Katz TM, Goldberg LH, Friedman PM. Dermatosis papulosa nigra treatment with fractional photothermolysis. Dermatol Surg. 2009;35:1840–1843.
    1. Rajesh G, Thappa DM, Jaisankar TJ, Chandrashekar L. Spectrum of seborrheic keratoses in South Indians: a clinical and dermoscopic study. Indian J Dermatol Venereol Leprol. 2011;77:483–488.
    1. Garcia MS, Azari R, Eisen DB. Treatment of dermatosis papulosa nigra in 10 patients: a comparison trial of electrodesiccation, pulsed dye laser, and curettage. Dermatol Surg. 2010;36:1968–1972.
    1. Polder KD, Landau JM, Vergilis-Kalner IJ, Goldberg LH, Friedman PM, Bruce S. Laser eradication of pigmented lesions: a review. Dermatol Surg. 2011;37:572–595.
    1. Kundu RV, Joshi SS, Suh KY, Boone SL, Huggins RH, Alam M, et al. Comparison of electrodesiccation and potassium-titanyl-phosphate laser for treatment of dermatosis papulosa nigra. Dermatol Surg. 2009;35:1079–1083.
    1. Reis VM. Dermatosis due to plants (phytodermatoses) An Bras Dermatol. 2010;85:479–489.
    1. Mill J, Wallis B, Cuttle L, Mott J, Oakley A, Kimble R. Phytophotodermatitis: case reports of children presenting with blistering after preparing lime juice. Burns. 2008;34:731–733.
    1. Sasseville D. Clinical patterns of phytodermatitis. Dermatol Clin. 2009;27:299–308.
    1. Dantzig PI. Immunosupressive and cytotoxic drugs in dermatology. Arch Dermatol. 1974;110:393–406.
    1. Al-Khenaizan S, Al-Berouti B. Flagellate pigmentation: a unique adverse effect of bleomycin therapy. Eur J Dermatol. 2011;21:146.
    1. Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol. 1994;131:700–702.
    1. Silveira JCB, Cunha BM, Estrella RR. Bleomycin- induced flagellate dermatitis. An Bras Dermatol. 2006;81:83–85.
    1. Abess A, Keel DM, Graham BS. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol. 2003;139:337–339.
    1. Poppe LM, Anders D, Kneitz H, Bröcker EB, Benoit S. Flagellate dermatitis caused by shiitake mushrooms. An Bras Dermatol. 2012;87:463–465.
    1. Chakrabarti N, Chattopadhyay C. Ashy dermatosis: a controversial entity. Indian J Dermatol. 2012;57:61–62.
    1. Cherobin AC, Oliveira FO, Baeta IG, Vale EC. Case for diagnosis. Ashy dermatosis. An Bras Dermatol. 2012;87:151–152.
    1. Vega-Memije ME, Domínguez-Soto L. Ashy dermatosis. Int J Dermatol. 2010;49:228–229.
    1. Novick NL, Phelps R. Erythema dyschromicum perstans. Int J Dermatol. 1985;24:630–633.
    1. Jablonska S. Ingestion of ammonium nitrate as a possible cause of erythema dyschromicum perstans (ashy dermatosis) Dermatologica. 1975;150:287–291.
    1. Lambert WC, Schwartz RA, Hamilton GB. Erythema dyschromicum perstans. Cutis. 1986;37(1):42–44.
    1. Henderson CD, Tschen JA, Schaefer DG. Simultaneously active lesions of vitiligo and erythema dyschromicum perstans. Arch Dermatol. 1988;124:1258–1260.
    1. Nelson MR, Lawrence AG, Staughton RC, Gazzard BG. Erythema dyschromicum perstans in an HIV antibody-positive man. Br J Dermatol. 1992;127:658–659.
    1. Kontochristopoulos GJ, Aroni K, Anagnostopoulos G, Nakopoulou L, Tassopoulos NC. Erythema dyschromicum perstans and hepatitis C virus infection. Int J Dermatol. 2001;40:346–348.
    1. Torrelo A, Zaballos P, Colmenero I, Mediero IG, de Prada I, Zambrano A. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol. 2005;19:422–426.
    1. Domínguez Soto L, Vega Memije ME, Arenas R, Waxtein Morgenstein L. Dermatosis cinecienta. A clinico-pathological study of 20 patients (1989-1990) Gac Med Mex. 1992;128:623–627.
    1. Baranda L, Torres-Alvarez B, Cortes-Franco R, Moncada B, Portales-Perez DP, Gonzalez-Amaro R. Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. Arch Dermatol. 1997;133:325–329.
    1. Combemale P, Faisant M, Guennoc B, Dupin M, Heyraud JD. Erythema dyschromicum perstans: report of a new case and critical review of the literature. J Dermatol. 1998;25:747–753.
    1. Katoulis AC, Stavrianeas NG, Georgala S, Katsarou-Katsari A, Koumantaki-Mathioudaki E, Antoniou C, et al. Familial cases of poikiloderma of Civatte: genetic implications in its pathogenesis? Clin Exp Dermatol. 1999;24:385–387.
    1. Katoulis AC, Stavrianeas NG, Katsarou A, Antoniou C, Georgala S, Rigopoulos D, et al. Evaluation of the role of contact sensitization and photosensitivity in the pathogenesis of poikiloderma of Civatte. Br J Dermatol. 2002;147:493–497.
    1. Katoulis AC, Stavrianeas NG, Panayiotides JG, Bozi E, Vamvasakis E, Kalogeromitros D, et al. Poikiloderma of Civatte: a histopathological and ultrastructural study. Dermatology. 2007;214(2):177–182.
    1. Katoulis AC, Stavrianeas NG, Georgala S, Bozi E, Kalogeromitros D, Koumantaki E, et al. Poikiloderma of Civatte: a clinical and epidemiological study. J Eur Acad Dermatol Venereol. 2005;19:444–448.
    1. Behroozan DS, Goldberg LH, Glaich AS, Dai T, Friedman PM. Fractional photothermolysis for treatment of poikiloderma of Civatte. Dermatol Surg. 2006;32:298–301.
    1. Meijs MM, Blok FA, de Rie MA. Treatment of poikiloderma of Civatte with the pulsed dye laser: a series of patients with severe depigmentation. J Eur Acad Dermatol Venereol. 2006;20:1248–1251.
    1. Tierney EP, Hanke CW. Treatment of Poikiloderma of Civatte with ablative fractional laser resurfacing: prospective study and review of the literature. J Drugs Dermatol. 2009;8:527–534.
    1. Rusciani A, Motta A, Fino P, Menichini G. Treatment of poikiloderma of Civatte using intense pulsed light source: 7 years of experience. Dermatol Surg. 2008;34:314–319.
    1. Barbato MT, Criado PR, Silva AK, Averbeck E, Guerine MB, Sá NB. Association of acanthosis nigricans and skin tags with insulin resistance. An Bras Dermatol. 2012;87:97–104.
    1. Boza JC, Trindade EN, Peruzzo J, Sachett L, Rech L, Cestari TF. Skin manifestations of obesity: a comparative study. J Eur Acad Dermatol Venereol. 2012;26:1220–1223.
    1. Puri N. A study of pathogenesis of acanthosis nigricans and its clinical implications. Indian J Dermatol. 2011;56:678–683.
    1. Hermanns-Lê T, Scheen A, Piérard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol. 2004;5:199–203.
    1. Lee SS, Jung NJ, Im M, Lee Y, Seo YJ, Lee JH. Acral-type malignant acanthosis nigricans associated with gastric adenocarcinoma. Ann Dermatol. 2011;23:S208–S210.
    1. Moore RL, Devere TS. Epidermal manifestations of internal malignancy. Dermatol Clin. 2008;26:17-29, vii.
    1. Fernandez-Flores A. Cutaneous amyloidosis: a concept review. Am J Dermatopathol. 2012;34:1–14.
    1. Chuang YY, Lee DD, Lin CS, Chang YJ, Tanaka M, Chang YT, et al. Characteristic dermoscopic features of primary cutaneous amyloidosis: a study of 35 cases. Br J Dermatol. 2012;167:548–554.
    1. Souza Jd, Júnior, Schettini RA, Tupinambá WL, Schettini AP, Chirano CA, Massone C. Localized primary cutaneous nodular amyloidosis: case report. An Bras Dermatol. 2011;86:987–990.
    1. Tanaka A, Arita K, Lai-Cheong JE, Palisson F, Hide M, McGrath JA. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol. 2009;161:1217–1224.
    1. Sakuma TH, Hans-Filho G, Arita K, Odashiro M, Odashiro DN, Hans NR, et al. Familial primary localized cutaneous amyloidosis in Brazil. Arch Dermatol. 2009;145:695–699.
    1. Lee DD, Lin MW, Chen IC, Huang CY, Liu MT, Wang CR, et al. Genome-wide scan identifies a susceptibility locus for familial primary cutaneous amyloidosis on chromosome 5p13.1-q11. Br J Dermatol. 2006;155:1201–1208.
    1. Dahdah MJ, Kurban M, Kibbi AG, Ghosn S. Primary localized cutaneous amyloidosis: a sign of immune dysregulation? Int J Dermatol. 2009;48:419–421.
    1. Venkataram MN, Bhushnurmath SR, Muirhead DE, Al-Suwaid AR. Frictional amyloidosis: a study of 10 cases. Australas J Dermatol. 2001;42:176–179.
    1. Bandhlish A, Aggarwal A, Koranne RV. A clinico-epidemiological study of macular amyloidosis from north India. Indian J Dermatol. 2012;57:269–274.
    1. Baxa U. Structural basis of infectious and non-infectious amyloids. Curr Alzheimer Res. 2008;5:308–318.
    1. Sugiura K, Muro Y, Futamura K, Matsumoto K, Hashimoto N, Nishizawa Y, et al. The unfolded protein response is activated in differentiating epidermal keratinocytes. J Invest Dermatol. 2009;129:2126–2135.
    1. Vijaya B, Dalal BS, Sunila, Manjunath GV. Primary cutaneous amyloidosis: a clinico-pathological study with emphasis on polarized microscopy. Indian J Pathol Microbiol. 2012;55:170–174.
    1. Garg A, Mahalingam M, Alavian C. Pruritic patches on the back and papules on the legs. Primary localized cutaneous amyloidosis (PLCA) (cutaneous lichen amyloidosis and macular amyloidosis) Arch Dermatol. 2007;143:255–260.
    1. Melo BL, Costa IS, Goes Cde A, Tigre CA, André NF. An unusual presentation of macular amyloidosis. An Bras Dermatol. 2011;86:S24–S27.
    1. Oiso N, Yudate T, Kawara S, Kawada A. Successful treatment of lichen amyloidosus associated with atopic dermatitis using a combination of narrowband ultraviolet B phototherapy, topical corticosteroids and an antihistamine. Clin Exp Dermatol. 2009;34:e833–e836.
    1. Fujisawa T, Shu E, Ikeda T, Seishima M. Primary localized cutaneous nodular amyloidosis that appeared in a patient with severe atopic dermatitis. J Dermatol. 2012;39:312–313.
    1. Hudacek KD, Haque MS, Hochberg AL, Cusack CA, Chung CL. An unusual variant of confluent and reticulated papillomatosis masquerading as tinea versicolor. Arch Dermatol. 2012;148:505–508.
    1. Ferreira LM, Diniz LM, Ferreira CJM. Confluent and reticulated papillomatosis of Gougerot and Carteaud: report of three cases. An Bras Dermatol. 2008;84:78–81.
    1. Davis MD, Weenig RH, Camilleri MJ. Confluent and reticulate papillomatosis (Gougerot-Carteaud syndrome): a minocycline-responsive dermatosis without evidence for yeast in pathogenesis. A study of 39 patients and a proposal of diagnostic criteria. Br J Dermatol. 2006;154:287–293.
    1. Scheinfeld N. Confluent and reticulated papillomatosis: a review of the literature. Am J Clin Dermatol. 2006;7:305–313.
    1. Xia Y, Marquart LN, Gunning ST. What is your diagnosis? Confluent and reticulate papillomatosis (Gougerot-Carteaud syndrome) Cutis. 2007;80:184,201-2.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa